REGEND001 Autologous Therapy Product ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
85特発性間質性肺炎1

85. 特発性間質性肺炎


臨床試験数 : 627 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05657184
(ClinicalTrials.gov)
May 14, 202115/11/2022Treatment of Idiopathic Pulmonary Fibrosis(IPF) by REGEND001An Open-labelled Clinical Study to Explore the Safety, Tolerability and Preliminary Efficacy of REGEND001 Autologous Therapy Product for Treatment of Idiopathic Pulmonary Fibrosis (IPF).Idiopathic Pulmonary FibrosisDrug: REGEND001 Autologous Therapy ProductRegend TherapeuticsPeking Union Medical College Hospital;Ruijin Hospital;The First Affiliated Hospital of Guangzhou Medical University;Regend Therapeutics XLotus (Jiangxi) Co, Ltd.Recruiting50 Years75 YearsAll24Phase 1/Phase 2China